Adarx Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.adarx.com
Efficacy, Safety, PK, PD and HRQoL of 2 Dose Levels and Regimens of ADX-324 in Preventing HAE Attacks Compared With Placebo in Participants With Type 1 and Type II HAE
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06960213
Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension
Phase 1
Recruiting
- Conditions
- Hypertension,EssentialHypertension
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06205628
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Phase 1
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05876312
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
🇦🇺Nucleus Network Brisbane, Brisbane, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05691361
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath